Effect of Panax notoginseng preparations on platelet function.
10.19540/j.cnki.cjcmm.20170901.004
- Author:
Yue LI
1
;
Feng-Wen YANG
1
;
Ming-Yan ZHANG
1
;
Zhao-Chen JI
1
;
Xin-Yao JIN
1
;
Ling LV
1
;
Jun-Hua ZHANG
1
Author Information
1. Center for Evidence-Based Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China.
- Publication Type:Journal Article
- Keywords:
Meta-analysis;
Panax notoginseng;
platelet function;
systematic review
- From:
China Journal of Chinese Materia Medica
2017;42(21):4226-4233
- CountryChina
- Language:Chinese
-
Abstract:
To systematically evaluate the effect of Panax notoginseng preparations (PNPs) on platelet function six literature databases including PubMed, EMbase, the Cochrane Library, CNKI, WanFang, and SinoMed were searched to collect RCTs of PNPs. RCTs reporting the outcomes of platelet function could be included. Biases were evaluated by Cochrane handbook. Two reviewers screened literature, extracted data and assessed the risk of bias of included studies independently. Inconsistency were solved by discussion.Meta-analysis was conducted by RevMan 5.3 software.A total of 36 RCTs were involved with the outcome including MPAR, PLT, TXB2 and safety. The results of systematic review showed that compared with placebo [SMD=1.84,95%CI(1.33,2.35),P<0.000 01] and non-antiplatelet agents [SMD=0.74,95%CI(0.19,1.28),P=0.008] PNPs can reduce the MPAR level; PNPs combined with non-antiplatelet agents can reduce MPAR [SMD=2.34,95%CI(1.14,3.54),P=0.000 1] and TXB2(SMD=1.25,95%CI(0.75,1.76),P<0.000 01]; PNPs combined with anti-platelet agents have better effect on MPAR [SMD=0.93,95%CI(0.58,1.29),P<0.000 01] and TXB2 [SMD=1.16,95%CI(0.74,1.58),P<0.000 01]. In terms of hemorrhagic adverse reactions, PNPs combined with anti-platelet agents haven't increase adverse events. Current evidences suggested that PNPs can reduce MPAR level and TXB2. PNPs combined with anti-platelet or non-antiplatelet agents can improve efficacy. However, due to the huge clinical heterogeneity and poor methodological quality, the evidence is not strng enough. Rigorous designed clinical trials are warranted.
